The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer

Summary

It has been shown that urokinase-type plasminogen activator (uPA) and its main inhibitor (PAI-1) have predictive value for therapy success in advanced breast cancer. Levels of the complex between uPA and PAI-1, formed when both molecules are in their active form, might have superior predictive power. Here, we investigate the association between levels of uPA:PAI-1 complex and rate of response to first-line systemic therapy for advanced breast cancer. Tumor tissues of 170 patients with advanced breast cancer were analyzed for uPA:PAI-1 complex concentrations using a quantitative enzyme-linked immunosorbent assay. The patients received either endocrine therapy (n=96) or chemotherapy (n=74) as first-line treatment after diagnosis of advanced disease. Of the endocrine treated patients, those with high levels of uPA:PAI-1 complex showed a shorter progression-free survival (PFS) compared to patients with lower uPA:PAI-1 complex levels (P=0.035). Furthermore, in the multivariate regression analysis a significant lower rate of response to first-line endocrine therapy was found in patients with high uPA:PAI-1 complex levels compared to patients with low uPA:PAI-1 complex levels (odds ratio (OR)=0.27, 95% CI, 0.09–0.59, P=0.018), in addition to the predictive impact of the steroid hormone receptor (ER/PgR) status (OR=2.68, 95% CI, 1.08–6.63, P=0.033). Complex levels did not predict efficacy of chemotherapy in patients with advanced breast cancer. The results show that the plasminogen activation system affects the response to endocrine therapy independent of steroid hormone receptor status and may be of help to further refine the indication for this treatment in individual patients. Further studies are warranted to explain this underlying resistance to endocrine therapy when uPA:PAI-1 levels are high.

Keywords

Advanced breast cancer - plasminogen activator inhibitor type-1 - predictive - uPA:PAI-1 complex - urokinase-type plasminogen activator

• References

• 1 Danø K, Andreasen PA, Grøndahl-Hansen J. et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
• 2 Andreasen PA, Kjoller L, Christensen L. et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
• 3 Schmitt M, Harbeck N, Thomssen C. et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-96.
• 4 Duffy MJ, Maguire TM, McDermott EW. et al. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999; 71: 130-5.
• 5 Jänicke F, Prechtl A, Thomssen C. et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
• 6 Look MP, Putten WLJ, van Duffy MJ. et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
• 7 Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.
• 8 Harbeck N, Kates RE, Look MP. et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified highrisk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 2002; 62: 4617-22.
• 9 Foekens JA, Look MP, Peters HA. et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-6.
• 10 Grebenschikov N, Sweep F, Geurts A. et al. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int J Cancer 1999; 81: 598-606.
• 11 Pedersen AN, Høyer-Hansen G, Brünner N. et al. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Immunol Methods 1997; 203: 55-65.
• 12 Pedersen AN, Christensen IJ, Stephens RW. et al. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000; 60: 6927-34.
• 13 Sten-Linder M, Seddighzadeh M, Engel G. et al. Prognostic importance of the uPA/PAI-1 complex in breast cancer. Anticancer Res 2001; 21: 2861-6.
• 14 Koenders AJM, Geurts-Moespot A, Zollingen S. et al. Progesterone and estradiol receptors in DMBA-induced mammary tumors before and after ovariectomy and after subsequent estradiol administration. In: Progesterone receptors in normal and neoplastic tissues (Progress in Cancer and therapy). McGuire W, Raynaud J, Baulieu E. New York, NY: Raven Press; 1977: 71-84.
• 15 Lowry OH, Rosebrough NJ, Farr AL. et al. Protein measurements with the folin reagent. J Biol Chem 1951; 193: 265-75.
• 16 Grebenschikov N, Geurts-Moespot A, Witte de H. et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997; 12: 6-14.
• 17 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-81.
• 18 Xing RH, Mazar A, Henkin J. et al. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997; 57: 3585-93.
• 19 Abidi SMA, Howard EW, Dmytryk JJ. et al. The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB- 231 and MCF-7 breast cancer cells. Clin Exp Metastasis 1998; 16: 235-41.
• 20 Levenson AS, Svoboda KM, Kwaan HC. et al. Agonist activity of anti-estrogen-receptor complexes to regulate urokinase activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Letters 1998; 125: 215-20.
• 21 Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001; 152: 741-52.
• 22 Knight 3rd WA, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer. J Clin Endocrinol Metab 1980; 09: 361-8.
• 23 Osborne CK, Yochmowitz MG, Knight 3rd WA. et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-8.